123 related articles for article (PubMed ID: 37202328)
21. Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.
Xue W; Zhang Y; Wang H; Zhang Y; Hu X
Front Immunol; 2021; 12():778746. PubMed ID: 34917092
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
Repmann R; Goldschmidt AJ; Richter A
Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
24. The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Yiu W; Chen J; Zhao B; Zhang W; Chen L; Liu H
Comput Math Methods Med; 2022; 2022():7341294. PubMed ID: 35392587
[TBL] [Abstract][Full Text] [Related]
25. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
26. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
28. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
30. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK; Uzzo R; Karam JA; Master VA; Donskov F; Suarez C; Albiges L; Rini B; Tomita Y; Kann AG; Procopio G; Massari F; Zibelman M; Antonyan I; Huseni M; Basu D; Ci B; Leung W; Khan O; Dubey S; Bex A
Lancet; 2022 Oct; 400(10358):1103-1116. PubMed ID: 36099926
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.
Massari F; Di Nunno V; Mollica V; Graham J; Gatto L; Heng D
Clin Genitourin Cancer; 2019 Apr; 17(2):e339-e344. PubMed ID: 30704796
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years].
May M; Kendel F; Hoschke B; Gilfrich C; Kiessig S; Pflanz S; Seidel M; Brookman-Amissah S
Urologe A; 2009 Sep; 48(9):1075-83. PubMed ID: 19562320
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
Karam JA; Puligandla M; Flaherty KT; Uzzo RG; Matin SF; Pins MR; Wood CG; Kane C; Jewett MAS; Kim SE; Dutcher JP; DiPaola RS; Haas NB
BJU Int; 2022 Jun; 129(6):718-722. PubMed ID: 34480522
[TBL] [Abstract][Full Text] [Related]
36. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.
Bandini M; Smith A; Zaffuto E; Pompe RS; Marchioni M; Capitanio U; Chun FK; Kapoor AB; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2018 Jan; 36(1):51-57. PubMed ID: 29022072
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK;
Lancet Oncol; 2022 Sep; 23(9):1133-1144. PubMed ID: 36055304
[TBL] [Abstract][Full Text] [Related]
38. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging.
Yu KJ; Keskin SK; Meissner MA; Petros FG; Wang X; Borregales LD; Gu C; Tamboli P; Matin SF; Wood CG; Karam JA
Cancer; 2018 Oct; 124(20):4023-4031. PubMed ID: 30276798
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
40. Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.
Roussel E; Verbiest A; Kinget L; Boeckx B; Zucman-Rossi J; Couchy G; Caruso S; Job S; de Reyniès A; De Wever L; Baldewijns M; Van Poppel H; Joniau S; Lambrechts D; Albersen M; Beuselinck B
Clin Genitourin Cancer; 2021 Dec; 19(6):e382-e394. PubMed ID: 34362692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
